NCT03917719 — "An Open-Label Extension Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy" trial site landscape

Public-registry site landscape for NCT03917719, “An Open-Label Extension Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy”, a Duchenne Muscular Dystrophy study sponsored by Catabasis Pharmaceuticals. All data below is from public sources; Eichor is not affiliated with the sponsor.

Trial	NCT03917719 (registry record)
Study title	An Open-Label Extension Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy
Official title	An Open-Label Extension Study of Edasalonexent in Pediatric Patients With Duchenne Muscular Dystrophy
Sponsor	Catabasis Pharmaceuticals
Condition(s)	Duchenne Muscular Dystrophy
Phase	PHASE3
Listed sites	23
Site countries	United States, Australia, Canada, Germany, Sweden, United Kingdom

Patient-friendly overview of this study: eichor.com/study/NCT03917719.

Free site-risk snapshot for this trial

Eichor generates a preliminary site-risk snapshot for NCT03917719 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Related trials

Other Duchenne Muscular Dystrophy trials

← Eichor home · All tracked trials · Duchenne Muscular Dystrophy studies · Weekly briefs

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →